New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.

LONDON (Reuters) - Sanofi-Aventis and Bristol-Myers Squibb , which are just recovering from defeating generic competition to their top-selling Plavix drug in the United States, now face a similar ...

The Food and Drug Administration on Tuesday said a Canadian company could sell a generic version of the anticoagulant Plavix, the biggest-selling drug for , the developer of Plavix and the marketing ...

Medco Health Solutions says it expects a generic version of the blockbuster Bristol-Myers Squibb and Sanofi-Aventis blood thinner Plavix to become available in the United States this year. The ...

News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

PARIS/LONDON (Reuters) - French drugmaker Sanofi-Aventis is preparing to sell its own generic version of the blockbuster heart medicine Plavix in France, a company spokesman said on Monday. Plavix, ...

Sanofi-Aventis and Bristol-Myers Squibb have cut a deal with a generic company that could keep a copycat version of their multibillion drug Plavix off the market until 2011. Sanofi-Aventis and Bristol ...

Please provide your email address to receive an email when new articles are posted on . ATLANTA — Clopidogrel monotherapy after 12 months of event free post-PCI dual antiplatelet therapy was ...

Patients with high-risk features undergoing elective PCI and treated with the more-potent antiplatelet agent ticagrelor (Brilinta; AstraZeneca) instead of clopidogrel fared no better with respect to ...

NEW YORK — Bristol-Myers Squibb Co. and Sanofi-Aventis said Monday that they filed for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version ...

Please provide your email address to receive an email when new articles are posted on . Patients with MI with nonobstructive coronary arteries, or MINOCA, have fewer recurrent events than those with ...

The Food and Drug Administration is adding its strongest warning to the label for Plavix, cautioning that some patients do not respond to the blockbuster blood thinner. The FDA said in a statement ...